CRISPR stock slides as CAR-T death overshadows signs of efficacy

One of the first 11 patients to receive CRISPR Therapeutics’ anti-CD19 allogeneic CAR-T cell therapy has died. The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.